DoP directs NPPA to desist from fixing ceiling prices on its
The DoP's directive to the NPPA in this regard came during the examination of a review application filed by pharma major Sun Pharmaceutical Industries against price fixation of “Volitra AQ injection (diclofenac sodium injection 75 mg/ml)” by the NPPA through its order No. S.O. 2195(E) [corrected SO No.2194(E)] dated 23.06.2016.
DoP asks NPPA to reconsider retail price fixation on Abbott’s
The DoP took up the matter and examined the argument from both the sides, before arriving at a decision to remand the review petition to the NPPA. Abbott, in its review application said that the NPPA fixed the retail price for the formulation based on recommendations of the Multi Disciplinary Committee (MDC) of Experts, using the average of
DoP junks Skymap Pharma review plea against NPPA
New Delhi: In a major setback to Skymap Pharmaceuticals Limited, the Department of Pharmaceuticals (DoP) has rejected the review application filed by the drugmaker against a notification issued by the National Pharmaceutical Pricing Authority (NPPA) for fixing the retail price of Fluconazole Tablets 300mg.
Challenges with Fixing the Ceiling Price Under the 2013 DPCO
The Department of Pharmaceuticals (DoP) has directed the NPPA to adopt the correct methodology in all such cases of calculating the ceiling price of scheduled formulations like ciprofloxacin 500 mg and ciprofloxacin 250 mg tablets as per para 4 (i) of DPCO, 2013 and provisions of existing Schedule-I by including market shares of only
DoP asks NPPA to review, verify Bharat Serum and Vaccine's
The Department of Pharmaceuticals (DoP) has issued an order disposing the review application of Bharat Serum and Vaccine (BSVL) to the National Pharmaceutical Pricing Authority (NPPA) instructing to verify the applicability of GST factor by cross-checking the documents submitted by BSVL pertaining to the formulation Human Normal Immunoglobulin.
